We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$25.4B
1-Year Est. Return
38.46%
This Fund
S&P 500
This Quarter
Est. Return
-3.12%
1 Year Est. Return
+38.46%
3 Year Est. Return
+154.38%
5 Year Est. Return
+223.79%
10 Year Est. Return
+923.25%
AUM
$19.3B
AUM Growth
-$1.05B
(-5.2%)
Cap. Flow
-$77.1M
Cap. Flow
% of AUM
-0.4%
Top 10 Holdings %
Top 10 Hldgs %
26.03%
Holding
1,444
New
138
Increased
405
Reduced
531
Closed
234
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$224M |
| 2 |
Brown-Forman Class B
BF.B
|
+$140M |
| 3 |
UnitedHealth
UNH
|
+$132M |
| 4 |
Monolithic Power Systems
MPWR
|
+$108M |
| 5 |
Oracle
ORCL
|
+$97.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$134M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
| 3 |
Micron Technology
MU
|
+$122M |
| 4 |
Pfizer
PFE
|
+$120M |
| 5 |
Microsoft
MSFT
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.43% |
| 2 | Healthcare | 14.49% |
| 3 | Financials | 11.62% |
| 4 | Consumer Discretionary | 10.92% |
| 5 | Industrials | 8.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Schneider National
SNDR
$6.27B
| $9.89M | 0.05% |
487,401
-7,900
| -2% | -$183K |
|
277
Carrier Global
CARR
$52B
| $9.82M | 0.05% |
276,296
-2,953
| -1% | -$116K |
|
278
Idexx Laboratories
IDXX
$45B
| $9.81M | 0.05% |
30,121
+122
| +0.4% | +$44.8K |
|
|
HZNP
279
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $9.6M | 0.05% |
+155,116
| New | +$10.8M |
|
280
Concentrix
CNXC
$1.5B
| $9.57M | 0.05% |
85,690
-51,275
| -37% | -$6.56M |
|
281
Dover
DOV
$28B
| $9.52M | 0.05% |
81,677
-119,706
| -59% | -$15.3M |
|
282
CBRE Group
CBRE
$42.7B
| $9.45M | 0.05% |
139,905
-364,982
| -72% | -$28.9M |
|
283
Fastenal
FAST
$59.9B
| $9.28M | 0.05% |
403,094
-38,388
| -9% | -$968K |
|
284
Moderna
MRNA
$25.4B
| $9.11M | 0.05% |
77,068
-72,955
| -49% | -$11.1M |
|
|
DFS
285
DELISTED
Discover Financial Services
DFS
| $9.09M | 0.05% |
100,014
-26,132
| -21% | -$2.64M |
|
286
FTI Consulting
FCN
$4.22B
| $8.83M | 0.05% |
53,286
-15,849
| -23% | -$2.67M |
|
287
QuidelOrtho
QDEL
$1.02B
| $8.76M | 0.05% |
122,512
-5,637
| -4% | -$504K |
|
288
U-Haul Holding Co
UHAL
$14.5B
| $8.75M | 0.05% |
171,750
-3,410
| -2% | -$179K |
|
289
Edwards Lifesciences
EW
$53.6B
| $8.55M | 0.04% |
103,512
+55,291
| +115% | +$5.32M |
|
290
Federal Realty Investment Trust
FRT
$10.2B
| $8.54M | 0.04% |
94,800
+11,180
| +13% | +$1.14M |
|
291
Idacorp
IDA
$8.21B
| $8.49M | 0.04% |
85,787
+453
| +0.5% | +$49.4K |
|
292
Exelon
EXC
$46.6B
| $8.39M | 0.04% |
224,100
-25,763
| -10% | -$1.14M |
|
293
Johnson Controls International
JCI
$92.6B
| $8.37M | 0.04% |
170,094
-273,315
| -62% | -$14.5M |
|
294
Walt Disney
DIS
$178B
| $8.31M | 0.04% |
88,064
+30,493
| +53% | +$3.26M |
|
295
Ametek
AME
$59.3B
| $8.26M | 0.04% |
72,868
+21,945
| +43% | +$2.63M |
|
296
J.M. Smucker
SJM
$12.7B
| $8.24M | 0.04% |
+59,954
| New | +$8.17M |
|
297
Textron
TXT
$15.3B
| $8.23M | 0.04% |
141,252
+39,996
| +39% | +$2.54M |
|
298
Cincinnati Financial
CINF
$26.5B
| $8.17M | 0.04% |
91,234
-259,175
| -74% | -$26.7M |
|
299
Boston Properties
BXP
$10.8B
| $8.13M | 0.04% |
108,486
-6,341
| -6% | -$539K |
|
300
Nordson
NDSN
$17.3B
| $8.08M | 0.04% |
38,072
-3,841
| -9% | -$861K |
|
Similar funds
VAI
Los Angeles Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Los Angeles Capital Management held 1,444 positions worth $19.3B, down 5.2% from $20.3B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Los Angeles Capital Management's Q3 2022 filing shows 138 new, 405 increased, 531 reduced and 234 closed positions. Its largest new stake was Neurocrine Biosciences: 791,966 shares worth $84.1M. The largest sale was Alphabet (Google) Class C, an estimated $134M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- Los Angeles Capital Management's largest Q3 2022 buy was Neurocrine Biosciences: 791,966 shares worth $84.1M.
- Los Angeles Capital Management added most to Broadcom in Q3 2022, an estimated $224M increase.
- Los Angeles Capital Management's biggest Q3 2022 reduction was Alphabet (Google) Class C, cutting an estimated $134M.
- Los Angeles Capital Management fully exited D.R. Horton in Q3 2022, selling an estimated $37.1M.
- Los Angeles Capital Management's ten largest holdings make up 26% of its $19.3B portfolio in Q3 2022.
- Los Angeles Capital Management opened 138 new positions and closed 234 in Q3 2022.
- Los Angeles Capital Management's portfolio value fell 5.2% quarter-over-quarter to $19.3B.
Based on Los Angeles Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.